Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention1: Saroglitazar: Dose:- 4 mg tablets.
Route:-Oral
Frequency :once daily
Duration:364 days/52 weeks of treatment period
Control Intervention1: Not Applicable: Not Applicable
Sponsors
Zydus Lifesciences Limited (formerly Cadila Healthcare Limited)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male and female patients aged �18 years 2. Patients who have been prescribed Saroglitazar for NAFLD will be included in this Phase 4 study (patients who use Saroglitazar for the first time) 3. Patients able to and willing to provide written informed consent and comply with the requirements of the study protocol 4. Patients with a prior documented diagnosis of NAFLD based on the AASLD criteria (Refer Appendix III for diagnostic criteria). NAFLD is defined either by previous histology or clinical imaging in individuals who consume little or no alcohol and do not have a cause for secondary hepatic steatosis or another cause of chronic liver disease. In addition, patients must have one of the following criteria to indicate ongoing NAFLD at screening: a. Liver stiffness through transient elastography, an LSM �8 kPa OR b. Serum ALT �45 U/L
Exclusion criteria
Exclusion criteria: 1.Consumption of alcohol for at least 90 consecutive days in last one year: >2 units of alcohol per day ( >14 units per week) for males and >1 unit of alcohol per day ( >7 units per week) for females. 2.History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis, cholestatic and metabolic liver diseases) and haemochromatosis. 3.Patient has known documented cirrhosis, either based on clinical criteria or liver histology or imaging. 4.Contraindications to Saroglitazar or any disease conditions affecting the ability to evaluate the effects of Saroglitazar. 5.History or other evidences of severe illness or any other conditions that would make patient, in the opinion of the investigator, unsuitable for the study. 6.Any previous history of ascites, hepatic encephalopathy, oesophageal varices or admission/emergency department visit for hepatic decompensation. 7. Women of child bearing potential: inability or unwillingness to practice contraception for the duration of the study. 8. Pregnant or breast feeding females.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in liver stiffness measurement performed by transient elastography and Frequency and severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)Timepoint: Baseline to Week 52 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in serum ALT valueTimepoint: Baseline to Week 24 and Week 52;Change in serum ASTTimepoint: Baseline to Week 24 and Week 52;Change in serum ALP valueTimepoint: Baseline to Week 24 and Week 52;Change in TG, HDL-C, LDL-C and non HDL-C levelsTimepoint: Baseline to Week 24 and Week 52;Change in body weight and BMITimepoint: Baseline to Week 24 and Week 52;To evaluate the safety of Saroglitazar 4 mg once daily in the study populationTimepoint: Baseline to Week 52 | — |
Countries
India
Contacts
Public ContactDr Kevinkumar Kansagra
Zydus Lifesciences Limited
Outcome results
None listed